BiotechTube

Recaticimab and Adebrelimab + GP chemotherapy

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Biliary Tract Carcinoma

Conditions

Biliary Tract Carcinoma

Trial Timeline

Jul 10, 2025 → Apr 20, 2028

NCT ID
NCT07062328

About Recaticimab and Adebrelimab + GP chemotherapy

Recaticimab and Adebrelimab + GP chemotherapy is a phase 2 stage product being developed by Sun Pharmaceutical for Biliary Tract Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07062328. Target conditions include Biliary Tract Carcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07062328Phase 2Recruiting

Competing Products

20 competing products in Biliary Tract Carcinoma

See all competitors
ProductCompanyStageHype Score
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Camrelizumab and Apatinib Plus GPSun PharmaceuticalPhase 1/2
41
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)ShionogiPhase 2
52
E6011 + PlaceboEisaiPhase 2
52
LenvatinibEisaiPhase 2
52
gemcitabine + cisplatinEli LillyPhase 2
52
gemcitabine + cisplatinEli LillyPhase 2
52
Ramucirumab + Merestinib + Cisplatin + Gemcitabine + Placebo Oral + Placebo IVEli LillyPhase 2
52
Baricitinib + PlaceboEli LillyPhase 2
52
AbemaciclibEli LillyPhase 2
52
SHR-A1811Jiangsu Hengrui MedicinePhase 2
52
SHR1258Jiangsu Hengrui MedicinePhase 2
52
ApatinibJiangsu Hengrui MedicinePhase 2
52
SHR-1210+GEMOXJiangsu Hengrui MedicinePhase 2
52
Rilvegostomig + Durvalumab + Gemcitabine/CisplatinAstraZenecaPhase 3
77
Durvalumab + Gemcitabine + CisplatinAstraZenecaPre-clinical
23
durvalumabAstraZenecaPhase 3
77
gemcitabine + cisplatin + Placebo + cisplatin + cediranib + gemcitabineAstraZenecaPhase 2/3
65
mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)] + Durvalumab + TremelimumabAstraZenecaPhase 1
33

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85